🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Moderate to Severe Atopic Dermatitis

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) NCT07355075Phase 2, Phase 31 site📍 Irving Turn Therapeutics · Tests: GX-03, Vehicle A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients NCT06946641Phase 11 site📍 Beijing Shanghai Qilu Pharmaceutical Research and Development Cente… · Tests: QLS12010, Placebo Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis NCT07298395Phase 232 sites📍 Birmingham📍 Hot Springs📍 Beverly Hills Enveda Therapeutics · Tests: ENV-294, Placebo Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis NCT06934252Phase 119 sites📍 Belconnen📍 Albion📍 Blacktown TRex Bio, Inc. · Tests: TRB-061, TRB-061, TRB-061, Placebo A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) NCT07239947Phase 110 sites📍 Hefei📍 Wuhu📍 Beijing Bambusa Therapeutics · Tests: BBT001, Placebo A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis NCT07037901Phase 230 sites📍 Lancaster📍 Los Angeles📍 Ocala Inmagene LLC · Tests: IMG-007, Placebo Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis NCT07762833Phase 31 site📍 Hangzhou Galderma R&D · Tests: Nemolizumab 30 mg, Placebo Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis NCT07042126Phase 33 sites📍 Beijing📍 Jinhua📍 Nanchang Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: 611, Matching placebo Dupixent and Narrowband UVB for Atopic Dermatitis NCT05285839Phase 41 site📍 East Windsor Psoriasis Treatment Center of Central New Jersey · Tests: Dupixent A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis NCT07330934Phase 21 site📍 Beijing Innovent Biologics (Suzhou) Co. Ltd. · Tests: Dupilumab, Placebo, IBI356 A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis NCT05391061n/a1 site📍 Seoul Pfizer · Tests: Abrocitinib Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland NCT05819463n/a9 sites📍 Basel📍 Bern📍 Buochs Swiss Society of Dermatology and Venereology A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema NCT06807281Phase 339 sites📍 Birmingham📍 North Little Rock📍 San Diego Pfizer · Tests: Abrocitinib A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis NCT07309055Phase 32 sites📍 Shenyang📍 Shanghai Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: SHR-1819 Injection, SHR-1819 Injection Placebo Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis NCT05042258Phase 41 site📍 Chicago Northwestern University · Tests: Dupilumab A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis NCT07399067Phase 21 site📍 Beijing Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI3002, Placebo, Dupilumab TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies NCT03621137n/a1 site📍 Amsterdam Academisch Medisch Centrum - Universiteit van Amsterdam (AM… · Tests: No study-specific intervention A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema NCT06807268Phase 347 sites📍 Birmingham📍 North Little Rock📍 San Diego Pfizer · Tests: Abrocitinib, Placebo A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis NCT07211542Phase 21 site📍 Guangzhou Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: SHR-1905 Injection, SHR-1905 Injection Blank Preparation IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients NCT06765005Phase 1, Phase 21 site📍 Hangzhou Shanghai Mabgeek Biotech.Co.Ltd · Tests: MG-K10 A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis NCT07558668Phase 114 sites📍 Arkansas City📍 Fremont📍 Plainfield Sitryx Therapeutics Ltd · Tests: SYX-5219 Oral Capsule ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis NCT06775860Phase 362 sites📍 Hefei📍 Wuhu📍 Beijing Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-332 Tablets, ICP-332 Placebo Tablets Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis NCT07660835Phase 21 site📍 San Antonio Galderma R&D · Tests: Nemolizumab A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis NCT07754786Phase 31 site📍 Guangzhou Innovent Biologics (Suzhou) Co. Ltd. · Tests: Dupilumab Injection, IBI3027 A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema NCT07216027Phase 242 sites📍 Phoenix📍 Phoenix📍 Scottsdale Pfizer · Tests: PF-08049820, Placebo Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis NCT06947993Phase 2105 sites📍 Birmingham📍 Birmingham📍 Fort Smith Novartis Pharmaceuticals · Tests: GHZ339, Placebo A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis NCT07643766Phase 29 sites📍 Encinitas📍 Los Angeles📍 Northridge Enveda Therapeutics · Tests: ENV-294, Placebo A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis NCT06815380n/a1 site📍 Aarhus Almirall, S.A. · Tests: No Intervention Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. NCT06899204n/a1 site📍 San Diego Pfizer · Tests: Abrocitinib A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis NCT07746817Phase 11 site📍 Melbourne Bionyra Pharma · Tests: BYN-001, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy